Updated Results of Rituximab Pre- and Post-BEAM with or without (90)Yttrium-Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-Cell Lymphoma

PURPOSE: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ((90)YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Chahoud, Jad, Sui, Dawen, Erwin, William D., Gulbis, Alison M., Korbling, Martin, Zhang, Mingzhi, Ahmed, Sairah, Alatrash, Gheath, Anderlini, Paolo, Ciurea, Stefan O., Oran, Betul, Fayad, Luis E., Bassett, Roland L., Jabbour, Elias J., Medeiros, L. Jeffrey, Macapinlac, Homer A., Young, Ken H., Khouri, Issa F.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955837/
https://ncbi.nlm.nih.gov/pubmed/29476021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3561
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars